OBJECTIVE: In contrast to rheumatoid arthritis (RA), the joint inflammation referred to as Jaccoud's arthritis that occurs in systemic lupus erythematosus (SLE) is nonerosive. Although the mechanism responsible is unknown, the antiosteoclastogenic cytokine interferon-alpha (IFNalpha), whose transcriptome is present in SLE monocytes, may be responsible. This study was undertaken to examine the effects of IFNalpha and lupus on osteoclasts and erosion in the (NZB x NZW)F(1) mouse model of SLE with K/BxN serum-induced arthritis. METHODS: Systemic IFNalpha levels in (NZB x NZW)F(1) mice were elevated by administration of AdIFNalpha. SLE disease was marked by anti-double-stranded DNA (anti-dsDNA) antibody titer and proteinuria, and Ifi202 and Mx1 expression represented the IFNalpha transcriptome. Microfocal computed tomography was used to evaluate bone erosions. Flow cytometry for CD11b and CD11c was used to evaluate the frequency of circulating osteoclast precursors (OCPs) and myeloid dendritic cells (DCs) in blood. RESULTS: Administration of AdIFNalpha to (NZB x NZW)F(1) mice induced osteopetrosis. (NZB x NZW)F(1) mice without autoimmune disease were fully susceptible to focal erosions in the setting of serum-induced arthritis. However, (NZB x NZW)F(1) mice with high anti-dsDNA antibody titers and the IFNalpha transcriptome were protected against bone erosions. AdIFNalpha pretreatment of NZW mice before K/BxN serum administration also resulted in protection against bone erosion (r(2) = 0.4720, P < 0.01), which was associated with a decrease in the frequency of circulating CD11b+CD11c- OCPs and a concomitant increase in the percentage of CD11b+CD11c+ cells (r(2) = 0.6330, P < 0.05), which are phenotypic of myeloid DCs. CONCLUSION: These findings suggest that IFNalpha in SLE shifts monocyte development toward myeloid DCs at the expense of osteoclastogenesis, thereby resulting in decreased bone erosion.
OBJECTIVE: In contrast to rheumatoid arthritis (RA), the joint inflammation referred to as Jaccoud's arthritis that occurs in systemic lupus erythematosus (SLE) is nonerosive. Although the mechanism responsible is unknown, the antiosteoclastogenic cytokine interferon-alpha (IFNalpha), whose transcriptome is present in SLE monocytes, may be responsible. This study was undertaken to examine the effects of IFNalpha and lupus on osteoclasts and erosion in the (NZB x NZW)F(1) mouse model of SLE with K/BxN serum-induced arthritis. METHODS: Systemic IFNalpha levels in (NZB x NZW)F(1) mice were elevated by administration of AdIFNalpha. SLE disease was marked by anti-double-stranded DNA (anti-dsDNA) antibody titer and proteinuria, and Ifi202 and Mx1 expression represented the IFNalpha transcriptome. Microfocal computed tomography was used to evaluate bone erosions. Flow cytometry for CD11b and CD11c was used to evaluate the frequency of circulating osteoclast precursors (OCPs) and myeloid dendritic cells (DCs) in blood. RESULTS: Administration of AdIFNalpha to (NZB x NZW)F(1) mice induced osteopetrosis. (NZB x NZW)F(1) mice without autoimmune disease were fully susceptible to focal erosions in the setting of serum-induced arthritis. However, (NZB x NZW)F(1) mice with high anti-dsDNA antibody titers and the IFNalpha transcriptome were protected against bone erosions. AdIFNalpha pretreatment of NZW mice before K/BxN serum administration also resulted in protection against bone erosion (r(2) = 0.4720, P < 0.01), which was associated with a decrease in the frequency of circulating CD11b+CD11c- OCPs and a concomitant increase in the percentage of CD11b+CD11c+ cells (r(2) = 0.6330, P < 0.05), which are phenotypic of myeloid DCs. CONCLUSION: These findings suggest that IFNalpha in SLE shifts monocyte development toward myeloid DCs at the expense of osteoclastogenesis, thereby resulting in decreased bone erosion.
Authors: Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger Journal: Nature Date: 1999-11-18 Impact factor: 49.962
Authors: Kurt Redlich; Silvia Hayer; Andrea Maier; Colin R Dunstan; Makiyeh Tohidast-Akrad; Susanne Lang; Birgit Türk; Peter Pietschmann; Wolfgang Woloszczuk; Silva Haralambous; George Kollias; Günter Steiner; Josef S Smolen; Georg Schett Journal: Arthritis Rheum Date: 2002-03
Authors: H Ji; D Gauguier; K Ohmura; A Gonzalez; V Duchatelle; P Danoy; H J Garchon; C Degott; M Lathrop; C Benoist; D Mathis Journal: J Exp Med Date: 2001-08-06 Impact factor: 14.307
Authors: H Travis Ichikawa; Thomas Conley; Tony Muchamuel; Jing Jiang; Susan Lee; Teresa Owen; Jennifer Barnard; Sarah Nevarez; Bruce I Goldman; Christopher J Kirk; R John Looney; Jennifer H Anolik Journal: Arthritis Rheum Date: 2012-02
Authors: Luciana Martins de Carvalho; Gonza Ngoumou; Ji Woo Park; Nadja Ehmke; Nikolaus Deigendesch; Naoki Kitabayashi; Isabelle Melki; Flávio Falcäo L Souza; Andreas Tzschach; Marcello H Nogueira-Barbosa; Virgínia Ferriani; Paulo Louzada-Junior; Wilson Marques; Charles M Lourenço; Denise Horn; Tilmann Kallinich; Werner Stenzel; Sun Hur; Gillian I Rice; Yanick J Crow Journal: Arthritis Rheumatol Date: 2017-08-22 Impact factor: 10.995
Authors: Nicholas A Young; Alexandra K Friedman; Benjamin Kaffenberger; Murugesan V S Rajaram; Daniel J Birmingham; Brad H Rovin; Lee A Hebert; Larry S Schlesinger; Lai-Chu Wu; Wael N Jarjour Journal: Mol Immunol Date: 2012-11-22 Impact factor: 4.407
Authors: Maria Angélica Pabón-Porras; Sebastian Molina-Ríos; Jorge Bruce Flórez-Suárez; Paola Ximena Coral-Alvarado; Paul Méndez-Patarroyo; Gerardo Quintana-López Journal: SAGE Open Med Date: 2019-09-13